Valeant Inks $54M Deal In DOJ's Salix Marketing Probe
Valeant Pharmaceuticals International Inc. has agreed to resolve a U.S. Department of Justice investigation into the sales and marketing practices of its subsidiary Salix Pharmaceuticals Ltd. for about $54 million, the...To view the full article, register now.
Already a subscriber? Click here to view full article